IRB #

IRB00008107

Title

RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Principal Investigator

Cristina Rodriguez

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of radiation therapy and cisplatin versus radiation therapy with cetuximab.

Medical Condition(s)

Oropharynx Cancer

Eligibility Criteria

1. Proven diagnosis of squamous cell carcinoma of the oropharynx
2. General history and physical examination by a radiation oncologist and medical oncologist within 8 weeks prior to registration
3. Examination by an ENT or head and neck surgeon, including laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 8 weeks prior to registration
4. Age ≥ 18
5. Other eligibility criteria also apply

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

The treatment phase of the study will last for up to 8 weeks. After that you will be asked to visit the office for follow up at 1 and 3 months from the end of treatment, then every 3 months through year 2, every 6 months for 3 years, then once a year for your lifetime.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

RTOG

Recruitment End

12/31/2014

Compensation Provided

No